Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

London mayor hosts innovation booster meeting

This article was originally published in Scrip

Executive Summary

The mayor of London, Boris Johnson, is hosting a meeting in the UK capital today (25 June) to discuss various options to boost innovation in the life sciences in London. These include the potential to establish a £10bn 'megafund' created by a mix of debt and equity finance that could bring together investors who would not normally invest in biomedical research and drug development. In return they could have a small percentage of the royalties from successful products or licensing revenues that result. Another option being discussed is to make use of the new InnovFin financing and advisory program set up jointly by the European Commission and the European Investment Bank (EIB). The initiative helps to share best practice between innovation and life science focused companies seeking to attract public and private investment in life sciences. It is expected that InnovFin will provide more than €24bn of new financing for research and innovation across Europe in the next seven years. The meeting is being hosted by the mayor along with MedCity, and the event is being supported by the EIB. Representatives from Eli Lilly, Pfizer, Silicon Valley Bank, EIB and JP Morgan are attending the event.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029074

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel